文献速递MDS 与骨髓增殖性肿瘤

Jaktinib(一种新型JAK抑制剂)在芦可替尼复发或难治性骨髓纤维化患者中的安全性和疗效:一项单臂、开放标签、2期、多中心研究

Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.
PubMed 文献 · Am J Hematol · 2023-07-19

这项2期多中心单臂开放标签研究纳入34例芦可替尼治疗后脾脏反应不足或脾脏再生长的中危或高危骨髓纤维化患者,接受jaktinib 100 mg每日两次治疗。第24周脾脏体积缩小≥35%的比例为32.4%,中危2或高危组为33.3%;50%的基线血红蛋白<100 g/L且不依赖输血的患者血红蛋白升高≥20 g/L;46.4%的患者总症状评分下降≥50%。常见≥3级治疗中出现的不良事件为血小板减少(32.4%)、贫血(32.4%)和白细胞增多(20.6%)。

要点

  • 第24周SVR35为32.4%(11/34,95%CI 19.1%-49.2%),中危2或高危组为33.3%(6/18,95%CI 16.3%-56.3%)。
  • 基线血红蛋白<100 g/L且不依赖输血的16例患者中,50%(8/16)在24周内血红蛋白升高≥20 g/L。
  • 46.4%(13/28)的患者第24周总症状评分下降≥50%;常见≥3级TEAE为血小板减少(32.4%)、贫血(32.4%)、白细胞增多(20.6%)。

核心结论

  • Jaktinib可能成为芦可替尼治疗后难治或复发骨髓纤维化患者的一种有前景的治疗选择。

研究设计与样本

  • 2期、单臂、开放标签、多中心研究,纳入当前诊断为中危或高危骨髓纤维化、且芦可替尼治疗后脾脏反应不足或脾脏再生长的患者。
  • 所有患者接受jaktinib 100 mg每日两次治疗。
  • 2021年7月6日至2022年1月24日共纳入34例芦可替尼难治或复发患者,其中52.9%(18/34)为DIPSS中危2或高危。

主要发现

  • 第24周SVR35在全部患者中为32.4%(11/34,95%CI 19.1%-49.2%),在中危2或高危组中为33.3%(6/18,95%CI 16.3%-56.3%)。
  • 基线血红蛋白<100 g/L且不依赖输血的16例患者中,50%(8/16)在24周内血红蛋白升高≥20 g/L。
  • 46.4%(13/28)的患者第24周总症状评分下降≥50%。
  • 最常见的≥3级治疗中出现的不良事件为血小板减少(32.4%)、贫血(32.4%)和白细胞增多(20.6%)。
  • 34例患者中13例(38.2%)发生严重不良事件,其中药物相关严重不良事件见于5例(14.7%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ruxolitinib has demonstrated efficacy in patients with myelofibrosis (MF). However, substantial number of patients may not respond after 3-6 months of treatment or develop resistance over time. In this phase 2 trial, patients with a current diagnosis of intermediate or high-risk MF who either had an inadequate splenic response or spleen regrowth after ruxolitinib treatment were enrolled. All patients received jaktinib 100 mg Bid. The primary endpoint was the proportion of patients with ≥35% reduction in spleen volume (SVR 35) at week 24. The secondary endpoints included change of MF-related symptoms, anemic response, and safety profile. From July 6, 2021, to January 24, 2022, 34 ruxolitinib-refractory or relapsed patients were enrolled, 52.9% (18 of 34) were DIPSS intermediate 2 or high risk. SVR 35 at week 24 was 32.4% (11 of 34, 95% CI 19.1%-49.2%) in all patients and 33.3% (6 of 18, 95% CI 16.3%-56.3%) in the intermediate 2 or high-risk group. A total of 50% (8 of 16) transfusion-independent patients with hemoglobin (HGB) <100 g/L at baseline had HGB elevation ≥20 g/L within 24 weeks. Furthermore, 46.4% (13 of 28) of patients had a ≥ 50% decrease in the total symptom score (TSS 50) at week 24. The most common grade ≥3 treatment-emergent adverse events (TEAEs) were thrombocytopenia (32.4%), anemia (32.4%), and leukocytosis (20.6%). In total, 13 (38.2%) of 34 patients had serious adverse events (SAE), of which drug-related SAEs were found in 5 patients (14.7%). These results indicate that jaktinib can be a promising treatment option for patients with MF who have either become refractory to or relapsed after ruxolitinib treatment.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Zhang Q, Liu Q, et al. Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study. Am J Hematol. 2023. PMID: 37466271. doi:10.1002/ajh.27031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。